Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04952792 | Study of Apixaban in Patients Receiving Hemodiafiltration | PHASE2 | COMPLETED | 11 | — | — | May 20, 2021 | Dec 15, 2022 | Sep 21, 2023 | 1 | Spain |
Determine the plasma concentrations of apixaban before, during and after renal replacement therapy (hemodialysis and hemodiafiltration)
| Arm | Type | Description |
|---|---|---|
| Apixaban | EXPERIMENTAL | Apixaban treatment, oral, 2.5 mg/12h, 28 days |
| Name | Type | Description |
|---|---|---|
| Apixaban 2.5 milligram Oral Tablet | DRUG | Apixaban 2.5mg/12h, oral, 28 days |
Inclusion Criteria: Adults (18 years or older). * Body weight ≥ 60 kg. * Diagnosis of chronic kidney disease on hemodialysis, clinically stable (with a minimum of 3 months of treatment) and nonvalvular atrial fibrillation in treatment with coumarins. * Patient candidate for change of anticoagulant...